- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Rozlytrek
Synonyms :
entrectinib
Class :
Anti-cancer and Tyrosine Kinase Inhibitor
Dosage forms & Strengths
ADULT DOSING
capsule:
100 mg
200 mg
Non-Small cell lung Cancer:
Entrectinib treats NSCLC, Non-small cell lung cancer, in the adults with ROS1-positive tumors. It is given as a 600 mg capsule orally, four times daily.
NTRK Fusion Tumors:
It is indicated in treating Neurotrophic Tyrosine Receptor Kinase Gene Fusion Solid Tumor. The oral dose given in the case is 600 mg four times daily.
600
mg
Orally
once a day
Capsule
600
mg
Orally
once a day
Capsule
Dosage forms & Strengths
It is indicated in treating Neurotrophic Tyrosine Receptor Kinase Gene Fusion Solid Tumor in children above 12 years.
The oral dose given in the case is 600 mg four times daily.
Safety and efficacy are not found in children below 12 years.
600
mg
Orally
once a day
Capsule
Safety and efficacy are not found in children below 12 years
may enhance the concentration of serum when combined with entrectinib
may enhance the concentration of serum when combined with entrectinib
may enhance the concentration of serum when combined with entrectinib
may enhance the concentration of serum when combined with entrectinib
may enhance the concentration of serum when combined with entrectinib
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 Inhibitors
when used together, entrectinib and alfuzosin both increase the QTc interval
when used together, entrectinib and apomorphine both increase the QTc interval
when used together, entrectinib and bedaquiline both increase the QTc interval
when used together, entrectinib and citalopram both increase the QTc interval
when used together, entrectinib and degarelix both increase the QTc interval
when used together, entrectinib and eliglustat both increase the QTc interval
erythromycin stearate increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
etravirine decreases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
fluconazole increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
fostamatinib increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when used together, entrectinib and gilteritinib both increase the QTc interval
when used together, entrectinib and haloperidol both increase the QTc interval
idelalisib increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when used together, entrectinib and isoflurane both increase the QTc interval
ketoconazole increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when used together, entrectinib and lefamulin both increase the QTc interval
when used together, entrectinib and levofloxacin both increase the QTc interval
when used together, entrectinib and lithium both increase the QTc interval
when used together, entrectinib and lumefantrine both increase the QTc interval
when used together, entrectinib and methadone both increase the QTc interval
when used together, entrectinib and midostaurin both increase the QTc interval
nefazodone increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when used together, entrectinib and osimertinib both increase the QTc interval
when used together, entrectinib and panobinostat both increase the QTc interval
when used together, entrectinib and quinine both increase the QTc interval
when used together, entrectinib and ranolazine both increase the QTc interval
when used together, entrectinib and risperidone both increase the QTc interval
when used together, entrectinib and romidepsin both increase the QTc interval
when used together, entrectinib and midostaurin both increase the QTc interval
when used together, entrectinib and sorafenib both increase the QTc interval
when used together, entrectinib and midostaurin both increase the QTc interval
when used together, entrectinib and trazodone both increase the QTc interval
when used together, entrectinib and vandetanib both increase the QTc interval
verapamil increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when used together, entrectinib and vorinostat both increase the QTc interval
when used together, entrectinib and ziprasidone both increase the QTc interval
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may diminish the concentration of serum when combined with entrectinib
may diminish the concentration of serum when combined with entrectinib
may diminish the concentration of serum when combined with entrectinib
may diminish the concentration of serum when combined with entrectinib
may diminish the concentration of serum when combined with entrectinib
entrectinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
entrectinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
entrectinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
entrectinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
QTc interval increases on taking entrectinib and lenvatinib together. Avoid or take an alternate drug
the effect of entrectinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, both increase the QTC interval
lapatinib increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased QTC interval goser
when both drugs are combined, there may be an increased QTC interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of entrectinib
midostaurin and entrecitinib, when used simultaneously, increase the QTc level
midostaurin and entrecitinib, when used simultaneously, increase the QTc level
when used together, entrectinib and albuterol both increase the QTc interval
when used together, entrectinib and arformoterol both increase the QTc interval
when used together, entrectinib and clomipramine both increase the QTc interval
when used together, entrectinib and imipramine both increase the QTc interval
when used together, entrectinib and protriptyline both increase the QTc interval
when used together, entrectinib and salmeterol both increase the QTc interval
tazemetostat decreases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when used together, entrectinib and trimipramine both increase the QTc interval
when ajmaline is used together with entrectinib, the risk or seriousness of QTc prolongation is enhanced
when both drugs are combined, there may be a reduced excretion rate of topotecan and result in an elevated level of serum concentration
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
Frequency defined:
>10%
Increased creatinine
Anemia
Hyperuricemia
Fatigue
Constipation
Dysgeusia
Increased AST
Edema
Lymphopenia
Increased ALT
Hyponatremia
Diarrhea
Dysesthesia
Nausea
Hypocalcemia
Hypophosphatemia
Dyspnea
Increased lipase
Hypoalbuminemia
Dizziness
Neutropenia
Myalgia
Cognitive impairment
Increased amylase
Hyperkalemia
Increased weight
Increased alkaline phosphatase
Cough
Vomiting
Pyrexia
Arthralgia
Vision disorders
Peripheral sensory neuropathy
Headache
Hypotension
Ataxia
Abdominal pain
Sleep
Urinary tract infection
Decreased appetite
Muscular weakness
Back pain
Extremity pain
Rash
Fatigue
1-10%
Mood disorders
Dehydration
Lung infection
Anemia
Neutropenia
Pneumonia
Dyspnea
Pleural effusion
Sepsis
Pulmonary embolism
Respiratory failure
Pyrexia
<1%:
Increased alkaline phosphatase
Hyponatremia
Rash
Vision disorders
Muscular weakness
Ataxia
Arthralgia
Mood disorders
Sleep disorders
Decreased appetite
Pain in extremity
Cough
Pregnancy consideration: As per the mechanism of action of entrectinib, it is rendered unsafe for the fetus. Pregnant women are advised to know about the potential risks.
Lactation: No data available regarding the excretion of entrectinib in breast milk. Hence, potential adverse effects and potential benefits should be compared and considered.
Pregnancy category:
Patient information leaflet
Generic Name: entrectinib
Pronounced: en- trek -ti-nib
Why do we use entrectinib?
Entrectinib is an anti-cancer agent of the tyrosine kinase inhibitor class. It treats Neurotrophic Tyrosine Receptor Kinase Gene Fusion Solid Tumors.
ADVERTISEMENT
